Current issue
Journal content
Articles in press
Archive
About the Journal
About the Polish Annals of Medicine
Editorial Board
Abstracting & indexing
Open Access policy
Charges
Affiliated institutions
Contact
Instructions
Peer review process
Guide for authors
Publication ethics
Ethics and Patient Consent
User License
Usage of third party materials
Disclaimer
Statement on Artificial Intelligence
Reviewers
Guide for reviewers
Review Form
RESEARCH PAPER
Allele frequencies of thiopurine S-methyltransferase (TPMT) variants in the Nigerian population
1
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile Ife, Osun State, Nigeria
2
Department of Pathology and Carney Centre for Pharmacogenomics, University of Otago, Christchurch, New Zealand
Submission date: 2016-03-30
Acceptance date: 2016-06-22
Online publication date: 2016-08-24
Publication date: 2020-03-22
Corresponding author
Ayorinde Adehin
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile Ife, Osun State, Nigeria. Tel.: +234 8022013470.
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile Ife, Osun State, Nigeria. Tel.: +234 8022013470.
Pol. Ann. Med. 2017;24(2):144-147
KEYWORDS
ABSTRACT
Introduction:
Thiopurine S-methyltransferase (TPMT) methylates clinically relevant thiopurine drugs most of which are noted for adverse reactions in certain users, largely due to polymorphisms in the TPMT gene.
Aim:
This study investigated the prevalence of functionally relevant TPMT alleles in the Nigerian population.
Material and methods:
One hundred eighty unrelated subjects consisting of 123 males and 57 females from the main Nigerian ethnicities (44 Igbo, 101 Yoruba, 23 Hausa and 12 from other minor ethnic groups) were genotyped for TPMT*2, *3B, *3C and *4 alleles using the iPLEX genotyping assay technique. The genotype calls were validated with Sanger sequencing in a random set of samples and the acquired data were assessed for Hardy–Weinberg equilibrium using the Fisher's exact test.
Results and discussion:
Defective TMPT alleles were found in individuals representing 10% of the study population. TPMT*3C constituted 9.4% (95% CI, 5.6–14.7) of all alleles detected, with one homozygote and 17 heterozygotes recorded. The prevalence of the TPMT*3C allele in the population conformed with Hardy–Weinberg equilibrium. TPMT*2, 3B and *4 were, however, not detected in the population.
Conclusions:
TPMT*3C was the only defective allele identified in Nigerians and may hence be the major underlying genetic contributor to adverse reactions due to thiopurine drugs in the population.
Thiopurine S-methyltransferase (TPMT) methylates clinically relevant thiopurine drugs most of which are noted for adverse reactions in certain users, largely due to polymorphisms in the TPMT gene.
Aim:
This study investigated the prevalence of functionally relevant TPMT alleles in the Nigerian population.
Material and methods:
One hundred eighty unrelated subjects consisting of 123 males and 57 females from the main Nigerian ethnicities (44 Igbo, 101 Yoruba, 23 Hausa and 12 from other minor ethnic groups) were genotyped for TPMT*2, *3B, *3C and *4 alleles using the iPLEX genotyping assay technique. The genotype calls were validated with Sanger sequencing in a random set of samples and the acquired data were assessed for Hardy–Weinberg equilibrium using the Fisher's exact test.
Results and discussion:
Defective TMPT alleles were found in individuals representing 10% of the study population. TPMT*3C constituted 9.4% (95% CI, 5.6–14.7) of all alleles detected, with one homozygote and 17 heterozygotes recorded. The prevalence of the TPMT*3C allele in the population conformed with Hardy–Weinberg equilibrium. TPMT*2, 3B and *4 were, however, not detected in the population.
Conclusions:
TPMT*3C was the only defective allele identified in Nigerians and may hence be the major underlying genetic contributor to adverse reactions due to thiopurine drugs in the population.
CONFLICT OF INTEREST
None declared.
REFERENCES (23)
1.
Fazel-Najafabadi E, Vahdat Ahar E, Fattahpour S, Sedghi M. Structural and functional impact of missense mutations in TPMT: an integrated computational approach. Comput Biol Chem. (59 Pt A):2015;(59 Pt A):48–55.
2.
Stocco G, Martelossi S, Barabino A, et al. TPMT genotype and the use of thiopurines in paediatric inflammatory bowel disease. Dig Liver Dis. 2005;37(12):940–945.
3.
Dhawan A, Ruwali M, Pant MC, Rahman Q, Parmar D. Association of genetic variability in enzymes metabolizing chemotherapeutic agents with treatment response in head and neck cancer cases. Asia Pac J Clin Oncol. 2016. http://dx.doi.org/10.1111/ajco... [Epub ahead of print].
4.
Farfan MJ, Salas C, Canales C, et al. Prevalence of TPMT and ITPA gene polymorphisms and effect on mercaptopurine dosage in Chilean children with acute lymphoblastic leukemia. BMC Cancer. 2014;28:299.
5.
Chouchana L, Narjoz C, Roche D, et al. Interindividual variability in TPMT enzyme activity: 10 years of experience with thiopurine pharmacogenetics and therapeutic drug monitoring. Pharmacogenomics. 2014;15(6):745–757.
6.
Ross CJ, Katzov-Eckert H, Dubé MP, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet. 2009;41(12):1345–1349.
7.
Hamdy SI, Hiratsuka M, Narahara K, et al. Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. Br J Clin Pharmacol. 2003;55(6):560–569.
8.
Ameyaw MM, Collie-Duguid ES, Powrie RH, Ofori-Adjei D, McLeod HL. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet. 1999;8(2):367–370.
9.
Zeglam HB, Benhamer A, Aboud A, et al. Polymorphisms of the thiopurine S-methyltransferase gene among the Libyan population. Libyan J Med. 2015;10:27053.
10.
Clayton TA, Lindon JC, Cloarec O, et al. Pharmacometabonomic phenotyping and personalized drug treatment. Nature. 2006;440(7087):1073–1077.
11.
National Population Commission, Abuja, Nigeria. 2008 Nigeria Demographic and Health Survey (NDHS Report). http://www.population.gov.ng/i.... [accessed 19.03.16].
12.
Tishkoff SA, Reed FA, Friedlaender FR, et al. The genetic structure and history of Africans and African Americans. Science. 2009;324(5930):1035–1044.
13.
McLeod HL, Pritchard SC, Githang'a J, et al. Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics. 1999;9(6):773–776.
14.
Janati Idrissi M, Samri I, Khabbal Y, El Hassouni M, Ouldim K. TPMT alleles in the Moroccans. Clin Res Hepatol Gastroenterol. 2015;39(4):e55–e56.
15.
Melaouhia S, Fékih M, Garat A, et al. Allele frequency of inosine triphosphate pyrophosphatase (ITPA) and thiopurine-S-methyl transferase (TPMT) genes in the Tunisian population. Clin Res Hepatol Gastroenterol. 2012;36(2):178–184.
16.
Hon YY, Fessing MY, Pui CH, Relling MV, Krynetski EY, Evans WE. Polymorphism of the thiopurine Smethyltransferase gene in African-Americans. Hum Mol Genet. 1999;8(2):371–376.
17.
Hiratsuka M, Inoue T, Omori F, Agatsuma Y, Mizugaki M. Genetic analysis of thiopurine methyltransferase polymorphism in a Japanese population. Mutat Res. 2000;448(1):91–95.
18.
Zhang JP, Guan YY, Xu AL, et al. Gene mutation of thiopurine S-methyltransferase in Uygur Chinese. Eur J Clin Pharmacol. 2004;60(1):1–3.
19.
Lee SS, Kim WY, Jang YJ, Shin JG. Duplex pyrosequencing of the TPMT*3C and TPMT*6 alleles in Korean and Vietnamese populations. Clin Chim Acta. 2008;398(1–2):82–85.
20.
Rossi AM, Bianchi M, Guarnieri C, Barale R, Pacifici GM. Genotype–phenotype correlation for thiopurine Smethyltransferase in healthy Italian subjects. Eur J Clin Pharmacol. 2001;57(1):51–54.
21.
Tai HL, Krynetski EY, Yates CR, et al. Thiopurine Smethyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet. 1996;58(4):694–702.
22.
Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol. 2001;19(8):2293–2301.
23.
Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci U S A. 1995;92(4):949–953.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
